GLP1R and heart failure: A large meta-analysis, involving 60,080 patients, reported that GLP-1 RA can reduce major adverse cardiovascular events (MACE) in type 2 diabetes patients with ASCVD by 14%, and lowers the risk of hospitalization due to heart failure (58).